Six-month outcomes of teduglutide treatment in adult patients with short bowel syndrome with chronic intestinal failure: A real-world French observational cohort study.

Date publication

décembre 2019

Journal

Clinical nutrition (Edinburgh, Scotland)

Auteurs

Membres identifiés du Cancéropôle Est :
Pr QUILLIOT Didier

Tous les auteurs :
Joly F, Seguy D, Nuzzo A, Chambrier C, Beau P, Poullenot F, Thibault R, Armengol Debeir L, Layec S, Boehm V, Lallemand J, Quilliot D, Schneider SM

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/31932048

Résumé

Teduglutide, a GLP-2-analog, has proven effective in two placebo-controlled studies in reducing parenteral support (PS) in patients with short bowel syndrome-associated intestinal failure (SBS-IF) after 24 weeks. The aim of this study was to describe in a real-life situation the effects of teduglutide treatment and their predictive factors.

Mots clés

GLP2- receptor agonist, Inflammatory bowel disease, Intestinal failure, Parenteral nutrition, Short-gut syndrome

Référence

Clin Nutr. 2019 Dec 23;: